Luke Mitcheson

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Craving and personal functioning as mediators of extended-release buprenorphine efficacy: A four-way decomposition analysis from a randomised trial.

Craving and personal functioning as mediators of extended-release buprenorphine efficacy: A four-way decomposition analysis from a randomised trial.

Journal: Addiction (Abingdon, England)

Published: December 16, 2025

Psychological change processes in alcohol use disorder: A qualitative study of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) with cognitive behavioural therapy.

Psychological change processes in alcohol use disorder: A qualitative study of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) with cognitive behavioural therapy.

Journal: Addiction (Abingdon, England)

Published: October 19, 2025

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trial.

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trial.

Journal: Addiction (Abingdon, England)

Published: June 11, 2025

Extended-release buprenorphine treatment for opioid use disorder: A mixed-methods study of response and experience.

Extended-release buprenorphine treatment for opioid use disorder: A mixed-methods study of response and experience.

Journal: Addiction (Abingdon, England)

Published: December 13, 2024

Patient experience of opioid use disorder treatment medications: a systematic review of contemporary qualitative research.

Patient experience of opioid use disorder treatment medications: a systematic review of contemporary qualitative research.

Journal: BMJ open

Published: December 04, 2024

Care models for coexisting serious mental health and alcohol/drug conditions: the RECO realist evidence synthesis and case study evaluation.

Care models for coexisting serious mental health and alcohol/drug conditions: the RECO realist evidence synthesis and case study evaluation.

Journal: Health technology assessment (Winchester, England)

Published: October 14, 2024

Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.

Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.

Journal: Addiction (Abingdon, England)

Published: August 22, 2024

Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.

Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.

Journal: EClinicalMedicine

Published: August 08, 2023

Patients' perceptions of self-administered dosing to opioid agonist treatment and other changes during the COVID-19 pandemic: a qualitative study.

Patients' perceptions of self-administered dosing to opioid agonist treatment and other changes during the COVID-19 pandemic: a qualitative study.

Journal: BMJ open

Published: March 21, 2023

Achieving integrated treatment: a realist synthesis of service models and systems for co-existing serious mental health and substance use conditions.

Achieving integrated treatment: a realist synthesis of service models and systems for co-existing serious mental health and substance use conditions.

Journal: The lancet. Psychiatry

Published: December 14, 2022

Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation.

Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation.

Journal: BMJ open

Published: October 21, 2022

Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.

Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.

Journal: Trials

Published: October 29, 2021

Showing 1-12 of 27

Last Updated: 09/26/2026